U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07323134) titled 'The Effect of Semaglutide on the Intestinal Flora in Obesity' on July 13, 2025.
Brief Summary: For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.
Study Start Date: Feb. 01
Study Type: OBSERVATIONAL
Condition:
Obesity
Intervention:
DRUG: Semaglutide Injection
Semaglutide Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Beijing Chao Yang Hospital
Published by HT Digital Content Services...